Ribavirin: Clinical Trials

225 trials of Ribavirin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

172 completed, 20 terminated, 19 unknown, 12 withdrawn. 225 Phase 3, 25 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3225Completed 172, Terminated 20, Unknown 19, Withdrawn 12, Not yet recruiting 1, Recruiting 1
Phase 225Completed 16, Unknown 4, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin

Trials (filtered) newest first · largest first

All 225 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of CKD Patients With HCV
SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients
Phase 2 / Phase 3Not yet recruitingTanta University502026-09-152026-08-20
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Favipiravir, Ribavirin, Dexamethasone - Lassa Fever
Phase 2 / Phase 3RecruitingIrrua Specialist Teaching Hospital17552025-05-022026-02-04
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever
Phase 3CompletedKhyber Medical University Peshawar2842024-12-172025-06-26
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19
Phase 2 / Phase 3UnknownThe Scientific and Technological Research Council of Turkey1002021-04-012021-04-02
New Antiviral Drugs for Treatment of COVID-19
Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : - COVID, Drug Effect
Phase 3UnknownMansoura University1002020-10-012020-09-03
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
TG-2349, DAG181, Ribavirin - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
Phase 3CompletedDongguan HEC TaiGen Biopharmaceuticals Co., Ltd.3702019-06-132021-02-04
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity
Ribavirin, Tenofovir - Hepatitis B, Chronic
Phase 3UnknownOttawa Hospital Research Institute242019-01-102021-09-14
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
Peginterferon alpha-2a + Ribavirin - Chronic Hepatitis
Phase 3CompletedCasa Sollievo della Sofferenza IRCCS11502018-12-012022-03-24
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
Ravidasvir, Danoprevir, Ritonavir - HCV
Phase 2 / Phase 3CompletedAscletis Pharmaceuticals Co., Ltd.4252017-07-012020-07-28
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV
Phase 3CompletedUniversity of Florida1772017-04-202020-02-26
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
SOF/VEL, RBV - Hepatitis C Virus Infection
Phase 3CompletedGilead Sciences1022016-12-262019-02-26
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
Sofosbuvir Oral Product, Ribavirin - Pharmacological Action
Phase 2 / Phase 3UnknownNational Liver Institute, Egypt412016-12-012016-12-19
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection
Phase 3CompletedAbbVie332016-11-212022-05-04
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
daclatasvir, asunaprevir, Ribavirin - Hepatitis C
Phase 3CompletedKaohsiung Medical University Chung-Ho Memorial Hospital702016-11-012019-01-09
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira - Hepatitis C
Phase 3CompletedEgyptian Liver Hospital722016-09-012017-12-27
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
Sofosbuvir, Ledipasvir, Ribavirin - Hepatitis C, Cirrhosis
Phase 3CompletedTehran University of Medical Sciences502016-09-012018-04-30
Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Grazoprevir 100 mg/day, Elbasvir 50 mg/d, Elbasvir 50 mg/day - Liver Transplantation, Hepatitis C
Phase 3WithdrawnFundacion Clinic per a la Recerca Biomédica2016-08-032025-06-22
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
SOF/VEL, RBV - Hepatitis C Virus Infection
Phase 3CompletedGilead Sciences1172016-07-252018-11-14
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Hepatitis C, Acute
Phase 3CompletedKirby Institute832016-06-012022-08-22
Swiss HCVree Trial
grazoprevir/elbasvir, ribavirin, Behavioural Intervention - Hepatitis C, HIV
Phase 3CompletedUniversity of Zurich1502016-06-012018-08-31

Showing 20 of 225. Sign in to see all of them.

Conditions studied

Hepatitis C (123)  ·  Hepatitis C, Chronic (122)  ·  Fibrosis (12)  ·  HIV Infections (10)  ·  Hepatitis (8)  ·  Liver Cirrhosis (8)  ·  Infections (6)  ·  Hepatitis, Chronic (4)  ·  Hepatitis B (3)  ·  Hepatitis B, Chronic (3)  ·  Liver Diseases (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  COVID-19 (2)  ·  Carcinoma, Hepatocellular (2)

Sponsors

Merck Sharp & Dohme LLC (30)  ·  AbbVie (23)  ·  Bristol-Myers Squibb (18)  ·  Gilead Sciences (7)  ·  Hoffmann-La Roche (6)  ·  Tanabe Pharma Corporation (6)  ·  AbbVie (prior sponsor, Abbott) (5)  ·  Janssen R&D Ireland (5)  ·  Bausch Health Americas, Inc. (4)  ·  Boehringer Ingelheim (4)  ·  Foundation for Liver Research (4)  ·  Janssen Pharmaceutical K.K. (4)  ·  Janssen-Cilag International NV (4)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4)  ·  Vertex Pharmaceuticals Incorporated (4)

Countries

United States (58)  ·  France (40)  ·  Spain (39)  ·  Germany (34)  ·  Canada (32)  ·  United Kingdom (32)  ·  Italy (27)  ·  Australia (25)  ·  Puerto Rico (23)  ·  Belgium (21)  ·  Russia (21)  ·  Japan (20)  ·  Poland (20)  ·  Austria (17)  ·  Egypt (16)

Top investigators

Ralph T. Doyle (4)  ·  Eric Cohen, MD (3)  ·  Fumitaka Suzuki, MD (3)  ·  Adriano Lazzarin, MD (2)

Results publications

PMID 29377566, PMID 25445400, PMID 26947564, PMID 20189674, PMID 22239511, PMID 22626609, PMID 25196718, PMID 26321288, PMID 26743093, PMID 26936417, PMID 27920566, PMID 29404492, PMID 29461687, PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 16122679, PMID 16287208, PMID 16614742, PMID 16890601, PMID 17593061, PMID 17635375, PMID 17654600, PMID 17656331, PMID 17850410, PMID 17894303, PMID 17894323, PMID 18167062, PMID 18237873, PMID 18266997, PMID 18318441, PMID 18463735, PMID 18848939, PMID 19052125, PMID 19053983, PMID 19187068, PMID 19284286, PMID 19291787, PMID 19327119, PMID 19330875, PMID 19445938, PMID 19527724, PMID 19625712, PMID 19676128, PMID 19684573, PMID 19721480, PMID 19747918, PMID 19749757, PMID 19766643

NIH funding

2014 (8), 2015 (4), 2004 (2), 2005 (2), 2009 (2), 2008 (1), 2016 (1), U01DK060309 (1), U01DK060324 (1), U01DK060327 (1), U01DK060329 (1), U01DK060335 (1), U01DK060340 (1), U01DK060341 (1), U01DK060342 (1)